Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Bracelet OS

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon May 11, 2023 6:46pm

188 Views

Post# 35444312

RE:RE:Bracelet OS

And this is partially what Matt Coffey said ... ". So for PFS the expectation on the control arm is about a six-month medium PFS. So we've got all patients out now 12 months beyond that. So I would say that that's reasonable – we'll have mature PFS for ASCO. [With respect to] OS we're starting to see the events now."

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing